Volume 20, Number 11—November 2014
Dispatch
Global Incidence of Carbapenemase-Producing Escherichia coli ST131
Table 3
Temporal distribution of Escherichia coli ST131 in 2 global studies, 2008–2013*
| Year |
Total no. E. coli |
No. carbapenem-nonsusceptible
E. coli |
No. (%) carbapenemase-producing E. coli |
Type of carbapenemases (no.) |
No. ST131 |
fimH30 |
Type of carbapenemases among ST131 (no.) |
| 2008 | 3,739 | 45 | 10 (0.3) | NDM-1 (9), IMP-1 (1) | 0 | 0 | 0 |
| 2009 | 5,913 | 63 | 21 (0.4) | NDM-1(16), NDM-4 (2), NDM-6 (1), OXA-48 (2) | 1 | 0 | NDM-1 (1) |
| 2010† | 8,951 | 71 | 17 (0.2) | KPC-2 (7), OXA-48 (10) | 17 | 10 | KPC-2 (7), OXA-48 (10) |
| 2011 | 10,009 | 81 | 21 (0.2) | KPC-2 (9), KPC-3 (1), NDM-1 (5), OXA-48 (5), OXA-163 (1) | 8 | 2 | KPC-2 (6), KPC-3 (1), NDM-1 (1) |
| 2012‡ | 14,275 | 97 | 35 (0.2) | KPC-2 (n12), KPC-3 (2), NDM-1 (7), NDM-5 (1), OXA-48 (11), OXA-244 (1), IMP-14 (1) | 9 | 7 | KPC-2 (5), OXA-48 (3), IMP-14 (1) |
| 2013 |
4,956 |
50 |
12 (0.2) |
KPC-2 (4), KPC-3 (3), NDM-1 (2), NDM-5 (1), VIM-1 (2) |
6 |
5 |
KPC-2 (3), KPC-3 (2), NDM-1 (1) |
| Total | 47,843 | 407 | 116 | NDM-1 (39), NDM-4 (2), NDM-5 (2), NDM-6 (1), KPC-2 (32), KPC-3 (6), OXA-48 (28), OXA-163 (1), OXA-244 (1), IMP-1 (1), IMP-14 (1), VIM-1 (2) | 41 | 24 | KPC-2 (21), KPC-3 (3), NDM-1 (3), OXA-48 (13), IMP-14 (1) |
*The 2 studies were the Merck Study for Monitoring Antimicrobial Resistance Trends (SMART) and the AstraZeneca global antimicrobial drug surveillance program. Isolates from SMART were not available for analysis in 2013: during 2008–2009, 1/32 (3%) E. coli isolates with carbapenemases from SMART were ST131 as opposed to 13/44 (30%) during 2011–2012. The limitation of the current study is that it uses a convenience set of isolates and differences over time could be related to differences in sampling rather than true increases in prevalence. Isolates from India were only obtained during 2008–10 while isolates from China were submitted in 2008, 2012 and 2013. NDM, New Delhi metallo-β-lactamase-1; IMP, imipenemase; OXA, oxacillinase, KPC, Klebsiella pneumonia carbapenemase; VIM, Verona integron–encoded metallo-β-lactamase.
†ST131 from 2010 should be interpreted with caution because 9 of the 17 isolates were submitted from a single hospital within Turkey. These isolates were positive for blaOXA-48, blaCTXM-15, and belonged to the H30-R sublineage. It is likely that this institution housed an outbreak during that time. If the 2010 isolates are removed from consideration, there was a substantial increase in ST131 toward the latter part of this study.
‡The AstraZeneca global surveillance program was initiated in 2012.
CrossRef reports the first page should be "e00377-13" not "e00377" in reference 15 "Price, Johnson, Aziz, Clabots, Johnston, Tchesnokova, et al., 2013".
Please verify the page numbers (e00377-13) (in reference 15 "Price, Johnson, Aziz, Clabots, Johnston, Tchesnokova, et al., 2013").
PRODUCTION NOTE: This table is online only.